2134 STAPHYLOCOCCAL NUCLEASE DOMAIN-CONTAINING PROTEIN 1 AS A POTENTIAL TISSUE MARKER FOR PROSTATE CANCER

Abstract

You have accessJournal of UrologyProstate Cancer: Markers II1 Apr 20102134 STAPHYLOCOCCAL NUCLEASE DOMAIN-CONTAINING PROTEIN 1 AS A POTENTIAL TISSUE MARKER FOR PROSTATE CANCER Hidetoshi Kuruma, Yuko Kamata, Hiroyuki Takahashi, Koji Igarashi, Takahiro Kimura, Kenta Miki, Jun Miki, Hiroshi Sasaki, Norihiro Hayashi, and Shin Egawa Hidetoshi KurumaHidetoshi Kuruma Tokyo, Japan More articles by this author , Yuko KamataYuko Kamata Tokyo, Japan More articles by this author , Hiroyuki TakahashiHiroyuki Takahashi Tokyo, Japan More articles by this author , Koji IgarashiKoji Igarashi Kanagawa, Japan More articles by this author , Takahiro KimuraTakahiro Kimura Tokyo, Japan More articles by this author , Kenta MikiKenta Miki Tokyo, Japan More articles by this author , Jun MikiJun Miki Tokyo, Japan More articles by this author , Hiroshi SasakiHiroshi Sasaki Tokyo, Japan More articles by this author , Norihiro HayashiNorihiro Hayashi Tokyo, Japan More articles by this author , and Shin EgawaShin Egawa Tokyo, Japan More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.2222AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Using high molecular-weight proteomic analysis, we previously showed that Staphylococcal nuclease domain-containing protein 1 (SND1) is highly expressed in recurrent androgen-insensitive prostate cancer tissues. SND1 is a component of the RNA-induced splicing complex that mediates RNA interference, leading to degradation of specific mRNAs. The objective of this study was to further characterize SND1 expression and to investigate its biological potential in prostate cancer. METHODS Radical prostatectomy specimens were obtained from 62 prostate cancer patients. SND1 immunohistochemical staining patterns were evaluated using an in-house polyclonal antibody. To assess the potential for tissue marker, immunostaining intensity of SND1 was compared with α-methylacyl-coenzyme A racemase (AMACR) that is a clinically applicant tissue marker protein. We confirmed SND1 mRNA expression in prostate cancer cells using an in situ hybridization technique. To determine the affection of SND1 for cell proliferation, we knocked down SND1 gene in prostate cancer PC-3 cells in vitro with small interfering RNA and observed cell growth with MTT assay. RESULTS In prostate cancer specimen, SND1 expressions were detected in 97%, whereas weakly or not at all expressed in all benign prostatic glands, including the hyperplastic glands and normal luminal cells. The immunostaining intensity scores in cancer, high-grade prostatic intraepithelial neoplasia (HGPIN), hyperplasia, and normal luminal cells were 1.7, 0.93, 0.24, and 0.27, (p<0.0001) for SND1, respectively, and 1.9, 1.0, 0.47, and 0.45, (p<0.0001) for AMACR, respectively. The intensity of SND1 immunoreactivity showed distinct correlation with Gleason score; more intense immunoreactivity being associated with higher specimen score (p=0.025). Expression of SND1 was also associated with high PSA but not with pathological T stage (p=0.012 and 0.95, respectively). By contrast, AMACR showed no relationship with any clinicopathological parameters including Gleason score, PSA level, and pathological T stage (p=0.65, 0.85 and 0.60, respectively). SND1 mRNA was also highly expressed in cancer cells but was negative to weak in noncancerous cells. The SND1 knocked down PC-3 cells were significantly suppressed in their growth by 47.3% as compared with negative control cells (p=0.030). CONCLUSIONS SND1 may have the potential for identification of the more aggressive and clinically significant prostate cancers. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e829 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Hidetoshi Kuruma Tokyo, Japan More articles by this author Yuko Kamata Tokyo, Japan More articles by this author Hiroyuki Takahashi Tokyo, Japan More articles by this author Koji Igarashi Kanagawa, Japan More articles by this author Takahiro Kimura Tokyo, Japan More articles by this author Kenta Miki Tokyo, Japan More articles by this author Jun Miki Tokyo, Japan More articles by this author Hiroshi Sasaki Tokyo, Japan More articles by this author Norihiro Hayashi Tokyo, Japan More articles by this author Shin Egawa Tokyo, Japan More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...